Article first published online: 4 DEC 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 6, pages 2134–2141, December 2012
How to Cite
Akuta, N., Suzuki, F., Seko, Y., Kawamura, Y., Sezaki, H., Suzuki, Y., Hosaka, T., Kobayashi, M., Hara, T., Kobayashi, M., Saitoh, S., Arase, Y., Ikeda, K. and Kumada, H. (2012), Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology, 56: 2134–2141. doi: 10.1002/hep.25949
Potential conflict of interest: Norio Akuta has received speakers' bureau from MSD K.K., and holds a right to get some loyalty from SRL. Inc.. Hiromitsu Kumada has received speakers' bureau from MSD K.K., Mitsubishi Tanabe Pharma, Dainippon Sumitomo Pharma, Bristol-Myers Squibb, and holds a right to get some loyalty from SRL. Inc.. Fumitaka Suzuki has received speakers' bureau from Bristol-Myers Squibb. The other authors have nothing to disclose.
Supported in part by Grants-in-Aid for scientific research and development from the Ministry of Health, Labor and Welfare and Ministry of Education Culture Sports Science and Technology, Government of Japan.
- Issue published online: 4 DEC 2012
- Article first published online: 4 DEC 2012
- Accepted manuscript online: 14 JUL 2012 03:10AM EST
- Manuscript Accepted: 17 JUN 2012
- Manuscript Revised: 30 MAY 2012
- Manuscript Received: 1 MAY 2012
The impact of amino acid (aa) 70 substitution in the core region on hepatocarcinogenesis and survival for liver-related death in patients of hepatitis C virus (HCV) genotype 1b (HCV-1b), who had not received antiviral therapy, is unknown. The relationships among aa 70 substitution, IL28B genotype, and hepatocarcinogenesis are also not clear. A total of 1,181 consecutive HCV-infected patients, who had not received antiviral therapy, were included in a follow-up study to determine predictive factors of hepatocarcinogenesis and survival for liver-related death. The cumulative hepatocarcinogenesis rates in HCV-1b of Gln70(His70) (glutamine (histidine) at aa 70) were significantly higher than those in HCV-1b of Arg70 (arginine at aa 70) and HCV-2a/2b. The cumulative survival rates for liver-related death in HCV-1b of Gln70(His70) were significantly lower than those in HCV-1b of Arg70 and HCV-2a/2b. Multivariate analysis identified gender (male), age (≥60 years), albumin (<3.9 g/dL), platelet count (<15.0 × 104/mm3), aspartate aminotransferase (≥67 IU/L), and HCV subgroup (HCV-1b of Gln70(His70)) as determinants of both hepatocarcinogenesis and survival rates for liver-related death. In HCV-1b patients, the cumulative change rates from Arg70 to Gln70(His70) by direct sequencing were significantly higher than those from Gln70(His70) to Arg70. In patients of Arg70 at the initial visit, the cumulative change rates from Arg70 to Gln70(His70) in IL28B rs8099917 non-TT genotype were significantly higher than those in the TT genotype. Conclusion: Substitution of aa 70 in the core region of HCV-1b is an important predictor of hepatocarcinogenesis and survival for liver-related death in HCV patients who had not received antiviral therapy. The IL28B genotype might partly affect changes over time of dominant amino acid in core aa 70 of HCV-1b. (HEPATOLOGY 2012;56:2134–2141)